Market Closed -
Nasdaq
21:30:01 03/05/2024 BST
|
5-day change
|
1st Jan Change
|
0.7289
USD
|
-2.68%
|
|
+2.71%
|
+27.25%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
16.73
|
625.1
|
786.9
|
126.1
|
87.09
|
128.9
|
-
|
-
|
Enterprise Value (EV)
1 |
16.73
|
625.1
|
620.4
|
126.1
|
87.09
|
128.9
|
128.9
|
128.9
|
P/E ratio
|
-0.41
x
|
-15.9
x
|
-10.8
x
|
-1.14
x
|
-1
x
|
-1.61
x
|
-1.85
x
|
-2.28
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.7
x
|
154
x
|
882
x
|
1,179
x
|
11.8
x
|
8.75
x
|
5.58
x
|
1.89
x
|
EV / Revenue
|
1.7
x
|
154
x
|
882
x
|
1,179
x
|
11.8
x
|
8.75
x
|
5.58
x
|
1.89
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-25
x
|
-12.1
x
|
-1.21
x
|
-
|
-2.19
x
|
-2.06
x
|
-2.15
x
|
FCF Yield
|
-
|
-4%
|
-8.26%
|
-82.8%
|
-
|
-45.6%
|
-48.6%
|
-46.6%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
47,723
|
109,469
|
125,496
|
131,249
|
152,039
|
176,838
|
-
|
-
|
Reference price
2 |
0.3505
|
5.710
|
6.270
|
0.9609
|
0.5728
|
0.7289
|
0.7289
|
0.7289
|
Announcement Date
|
19/03/20
|
25/02/21
|
24/02/22
|
15/03/23
|
14/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
9.862
|
4.046
|
0.892
|
0.107
|
7.379
|
14.73
|
23.1
|
68.05
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-15.78
|
-30.17
|
-72.75
|
-114.6
|
-83.35
|
-74.99
|
-80.5
|
-63.75
|
Operating Margin
|
-160.06%
|
-745.67%
|
-8,156.05%
|
-107,090.65%
|
-1,129.52%
|
-509%
|
-348.48%
|
-93.68%
|
Earnings before Tax (EBT)
1 |
-18.16
|
-31.98
|
-70.36
|
-107.7
|
-82.2
|
-75.13
|
-80.63
|
-63.05
|
Net income
1 |
-18.64
|
-32.22
|
-70.47
|
-107.8
|
-82.46
|
-77.53
|
-80.63
|
-62.1
|
Net margin
|
-189.06%
|
-796.34%
|
-7,900.22%
|
-100,708.41%
|
-1,117.56%
|
-526.2%
|
-349.06%
|
-91.26%
|
EPS
2 |
-0.8600
|
-0.3600
|
-0.5800
|
-0.8400
|
-0.5700
|
-0.4533
|
-0.3933
|
-0.3200
|
Free Cash Flow
1 |
-
|
-24.97
|
-64.99
|
-104.4
|
-
|
-58.81
|
-62.66
|
-60.03
|
FCF margin
|
-
|
-617.23%
|
-7,285.76%
|
-97,551.4%
|
-
|
-399.14%
|
-271.25%
|
-88.21%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/03/20
|
25/02/21
|
24/02/22
|
15/03/23
|
14/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
0.2
|
0.074
|
0.085
|
-
|
-
|
0.022
|
0.675
|
1.358
|
2.101
|
3.245
|
0.8
|
0.05
|
1.417
|
12.47
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-17.25
|
-24.22
|
-24.78
|
-29.25
|
-29.43
|
-31.14
|
-25.57
|
-23.05
|
-17.82
|
-16.9
|
-21.33
|
-21.97
|
-19.57
|
-12.12
|
Operating Margin
|
-8,625.5%
|
-32,722.97%
|
-29,148.24%
|
-
|
-
|
-141,536.36%
|
-3,788.44%
|
-1,697.57%
|
-848.26%
|
-520.8%
|
-2,666.04%
|
-43,942%
|
-1,381.39%
|
-97.25%
|
Earnings before Tax (EBT)
1 |
-17.56
|
-20.75
|
-25.08
|
-29.42
|
-29.29
|
-23.9
|
-25.11
|
-22.53
|
-17.36
|
-17.2
|
-21.43
|
-22.07
|
-19.6
|
-12.06
|
Net income
1 |
-17.58
|
-20.76
|
-25.1
|
-29.43
|
-29.31
|
-23.92
|
-25.14
|
-22.55
|
-17.4
|
-17.38
|
-21.63
|
-22.37
|
-20.24
|
-13.26
|
Net margin
|
-8,791.5%
|
-28,059.46%
|
-29,530.59%
|
-
|
-
|
-108,718.18%
|
-3,724.44%
|
-1,660.53%
|
-828.18%
|
-535.44%
|
-2,703.54%
|
-44,742%
|
-1,428.44%
|
-106.34%
|
EPS
2 |
-0.1400
|
-0.1700
|
-0.2000
|
-0.2300
|
-0.2300
|
-0.1800
|
-0.1900
|
-0.1600
|
-0.1100
|
-0.1200
|
-0.1400
|
-0.1400
|
-0.1200
|
-0.0733
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
04/11/21
|
24/02/22
|
09/05/22
|
08/08/22
|
08/11/22
|
15/03/23
|
04/05/23
|
03/08/23
|
02/11/23
|
14/03/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
166
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-25
|
-65
|
-104
|
-
|
-58.8
|
-62.7
|
-60
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
1.22
|
5.16
|
9.6
|
-
|
1.5
|
2.5
|
3.1
|
Capex / Sales
|
-
|
30.23%
|
578.14%
|
8,972.9%
|
-
|
10.18%
|
10.82%
|
4.56%
|
Announcement Date
|
19/03/20
|
25/02/21
|
24/02/22
|
15/03/23
|
14/03/24
|
-
|
-
|
-
|
Last Close Price
0.7289
USD Average target price
5
USD Spread / Average Target +585.97% Consensus |
1st Jan change
|
Capi.
|
---|
| +27.25% | 129M | | -1.43% | 104B | | +8.96% | 105B | | +4.40% | 22.94B | | -12.15% | 22.34B | | -4.36% | 19.25B | | -39.98% | 17.08B | | -10.04% | 16.96B | | +6.79% | 14.16B | | +38.61% | 12.63B |
Bio Therapeutic Drugs
|